These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 30136439)
1. Nucleic Acid-Targeted Small Molecules have Therapeutic Potential in the Treatment of Spinal Muscular Atrophy: Small-molecule drugs that can selectively bind RNA and modulate pre-mRNA splicing have potential as a treatment strategy for human disease, including spinal muscular atrophy. Am J Med Genet A; 2018 Aug; 176(8):1698-1699. PubMed ID: 30136439 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy. Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466 [TBL] [Abstract][Full Text] [Related]
3. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells. Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536 [TBL] [Abstract][Full Text] [Related]
4. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Sivaramakrishnan M; McCarthy KD; Campagne S; Huber S; Meier S; Augustin A; Heckel T; Meistermann H; Hug MN; Birrer P; Moursy A; Khawaja S; Schmucki R; Berntenis N; Giroud N; Golling S; Tzouros M; Banfai B; Duran-Pacheco G; Lamerz J; Hsiu Liu Y; Luebbers T; Ratni H; Ebeling M; Cléry A; Paushkin S; Krainer AR; Allain FH; Metzger F Nat Commun; 2017 Nov; 8(1):1476. PubMed ID: 29133793 [TBL] [Abstract][Full Text] [Related]
6. Rewriting the (tran)script: Application to spinal muscular atrophy. Ratni H; Mueller L; Ebeling M Prog Med Chem; 2019; 58():119-156. PubMed ID: 30879473 [TBL] [Abstract][Full Text] [Related]
7. Small Molecules in Development for the Treatment of Spinal Muscular Atrophy. Calder AN; Androphy EJ; Hodgetts KJ J Med Chem; 2016 Nov; 59(22):10067-10083. PubMed ID: 27490705 [TBL] [Abstract][Full Text] [Related]
8. Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy. Woll MG; Qi H; Turpoff A; Zhang N; Zhang X; Chen G; Li C; Huang S; Yang T; Moon YC; Lee CS; Choi S; Almstead NG; Naryshkin NA; Dakka A; Narasimhan J; Gabbeta V; Welch E; Zhao X; Risher N; Sheedy J; Weetall M; Karp GM J Med Chem; 2016 Jul; 59(13):6070-85. PubMed ID: 27299569 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide CRISPR-Cas9 Screen Identifies Leukemia-Specific Dependence on a Pre-mRNA Metabolic Pathway Regulated by DCPS. Yamauchi T; Masuda T; Canver MC; Seiler M; Semba Y; Shboul M; Al-Raqad M; Maeda M; Schoonenberg VAC; Cole MA; Macias-Trevino C; Ishikawa Y; Yao Q; Nakano M; Arai F; Orkin SH; Reversade B; Buonamici S; Pinello L; Akashi K; Bauer DE; Maeda T Cancer Cell; 2018 Mar; 33(3):386-400.e5. PubMed ID: 29478914 [TBL] [Abstract][Full Text] [Related]
10. A synthetic small molecule stalls pre-mRNA splicing by promoting an early-stage U2AF2-RNA complex. Chatrikhi R; Feeney CF; Pulvino MJ; Alachouzos G; MacRae AJ; Falls Z; Rai S; Brennessel WW; Jenkins JL; Walter MJ; Graubert TA; Samudrala R; Jurica MS; Frontier AJ; Kielkopf CL Cell Chem Biol; 2021 Aug; 28(8):1145-1157.e6. PubMed ID: 33689684 [TBL] [Abstract][Full Text] [Related]
11. Small molecule targeting of RNA structures in neurological disorders. Angelbello AJ; Chen JL; Disney MD Ann N Y Acad Sci; 2020 Jul; 1471(1):57-71. PubMed ID: 30964958 [TBL] [Abstract][Full Text] [Related]
14. Bringing RNA into the fold: Small molecules find new targets in RNA to combat disease. Chakradhar S Nat Med; 2017 May; 23(5):532-534. PubMed ID: 28475574 [No Abstract] [Full Text] [Related]
15. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Pellizzoni L; Kataoka N; Charroux B; Dreyfuss G Cell; 1998 Nov; 95(5):615-24. PubMed ID: 9845364 [TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy. Pinard E; Green L; Reutlinger M; Weetall M; Naryshkin NA; Baird J; Chen KS; Paushkin SV; Metzger F; Ratni H J Med Chem; 2017 May; 60(10):4444-4457. PubMed ID: 28441483 [TBL] [Abstract][Full Text] [Related]
18. Target-Directed Approaches for Screening Small Molecules against RNA Targets. Haniff HS; Knerr L; Chen JL; Disney MD; Lightfoot HL SLAS Discov; 2020 Sep; 25(8):869-894. PubMed ID: 32419578 [TBL] [Abstract][Full Text] [Related]
19. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts. Farrelly-Rosch A; Lau CL; Patil N; Turner BJ; Shabanpoor F Neurochem Int; 2017 Sep; 108():213-221. PubMed ID: 28389270 [TBL] [Abstract][Full Text] [Related]
20. Early Splicing Complexes and Human Disease. Nagasawa CK; Garcia-Blanco MA Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]